In this region, global intra-uterine contraceptive devices market is projected to reach USD 4,851.2 million by 2024 from USD 3,684.1 million in 2016, at a CAGR of 3.5% in the forecast period 2017 to 2024.
The global intra-uterine contraceptive devices market is segmented on the basis of product type, end user, and geography.
The global intra-uterine contraceptive devices market is segmented into 2 product types, namely copper IUCD and hormonal IUCD.
On the basis of end users the market is segmented into hospitals, gynaecology clinics, and community healthcare. In 2017, the hospital segment is expected to dominate the market and is expected to continue this trend till 2024.
Market Overview
Drivers
Rising Cases of Chronic Diseases
Rising Demand of Self-Injection Devices
Growth of Biologics Market
Technological Advancements and Innovations in Drug Delivery Market
Restraints
Needlestick Injuries and Infections
High Cost of Development
Strict Regulatory Framework
Opportunity
Increasing Demand for Generic and Biosimilar Drugs
Generics
Biosimilars
Increasing Demand for Contraceptive Injectables
Increasing Demand for Self-Administration of Drugs
Challenges
Alternative Route of Drug Administration
Product Recall
Stability of Products
Sterility of Injections
Global intra-uterine contraceptive devices (IUCD) market competition by top players including:
Bayer AG dominated the IUCD market accounting largest market share followed by Teva Pharmaceuticals Industries Ltd., and Mona Lisa N.V. along with others such as include:
DKT International
Egemen International
Melbea AG
Ocon Medical Ltd.
Pregna International Limited
Medical Engineering Corporation SA
SMB Corporation and Meril Life Sciences Pvt. Ltd.
Medu Scientific Ltd, China RH Contraceptives Co., Ltd
Sanghai Jolly Medical Education Co., Ltd
Bernstein Leibhard LLP
Zheijang Daji Medical Instruments, Ltd.
Nimble International
AME Line, Technico
Cepeo
Contraceptivos
Injeflex Ind And Com Ltda
Bersil
Amed.
Key Topics Covered:
1. Introduction
2. Market Segmentation
3. Market Overview
4. Executive Summary
5. Premium Insights
6. Global Injectable Drug Delivery Market, Regulatory
7. Global Injectable Drug Delivery Market, by Type
8. Global Injectable Drug Delivery Market, by Application
9. Global Injectable Drug Delivery Market, by Usage Pattern
10. Global Injectable Drug Delivery Market, by Mode of Administration
11. Global Injectable Drug Delivery Market, by End User
12. Global Injectable Drug Delivery Market, by Distribution Channel
13. Global Injectable Drug Delivery Market, by Geography
14. Global Injectable Drug Delivery Market, Company Share
15. Company Profiles
AME Line, Technico
Amed.
Bayer AG
Bernstein Leibhard LLP
Bersil
Cepeo
Contraceptivos
Egemen International
Injeflex Ind And Com Ltda
KT International
Medical Engineering Corporation SA
Medu Scientific Ltd, China RH Contraceptives Co., Ltd
PureTech Health plc ("PureTech" or the "Company") today announces its results for the year ended December 31, 2023, as well as its cash balance as of the first quarter ended March 31, 2024. The following information represents select highlights from...
Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CHINA, HONG KONG, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR...
The Balance RehabClinic, renowned for its luxury mental health and addiction services, proudly announces its expansion into The Balance Healthcare Group: a collection of premium mental health solutions tailored for affluent individuals. These new...
Zest Dental Solutions, a global leader in innovative dental solutions proudly announces a strategic partnership with The Pathway. Founded by Justin Moody, DDS and based in Arizona, The Pathway is a continuing education program that teaches dentists...
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...